March 2, 2017
NICE’s approval of Merck’s Erbitux combination gives more choice for mCRC patients in England
English wild-type metastatic colorectal cancer (mCRC) patients are getting more choice to a first-line effective treatment, as the UK National Institute for Health and Care Excellence (NICE) gave a positive Final Appraisal Determination (FAD) recommending the routine National Health Service (NHS) use of Merck’s Erbitux (cetuximab) in combination with either Folfiri or Folfox.